ENTITY
Hangzhou Tigermed Consulting C

Hangzhou Tigermed Consulting C (3347 HK)

107
Analysis
Health CareChina
Hangzhou Tigermed Consulting Co.,Ltd. provides professional clinical research services for domestic and foreign pharmaceutical and health-related research and development. The Company's main services include clinical trial technology services, data management, and statistical analysis. Hangzhou Tigermed Consulting offers services worldwide.
more
Refresh
04 Sep 2021 22:37

Novotech Health IPO Initiation: On-Demand Science

Novotech is set to pre-market an HKEx IPO to raise up to $1.5 bn. Novotech’s fundamentals are solid and the IPO is worth a look for investors...

Logo
290 Views
Share
11 Aug 2021 09:00

Pre-IPO Asymchem Laboratories - The Strength and the Concerns

The article mainly analyzed Asymchem Laboratories in terms of the industry characteristics, the strength of its business, the comparison with...

Logo
273 Views
Share
bullishWuxi Biologics
20 Jul 2021 18:54

Wuxi Biologics Placement - Similar Deal Will Yield Similar Results

Wuxi Biologics Holdings is looking to raise up to US$1.3bn by selling about 1.8% of Wuxi Biologics (2269 HK). This is the company's 15th placement...

Logo
352 Views
Share
06 Jul 2021 09:05

Pre-IPO Novotech Holdings - The Future Would Not Be Easy

This article analyzed Novotech in terms of the industry characteristics, comparison with peers (revenue growth rate, margins, etc.), the concerns...

Logo
571 Views
Share
bearishLinkDoc
24 Jun 2021 09:13

LinkDoc Technology (LDOC.US) - Here Are the Concerns

This article mainly analyzed concerns on LinkDoc in terms of main revenue source, profitability compared with peers, investment in R&D, barriers on...

Logo
239 Views
Share
x